HomeComparePFE vs AXON

PFE vs AXON: Dividend Comparison 2026

PFE yields 6.20% · AXON yields 0.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $30.7K in total portfolio value· pulled ahead in Year 8
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
AXON
AXON
● Live price
0.48%
Share price
$415.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$49.72
Full AXON calculator →

Portfolio growth — PFE vs AXON

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFEAXON
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + AXON cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
AXON pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
AXON
Annual income on $10K today (after 15% tax)
$40.96/yr
After 10yr DRIP, annual income (after tax)
$42.26/yr
At 15% tax rate, PFE beats the other by $23,086.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + AXON for your $10,000?

PFE: 50%AXON: 50%
100% AXON50/50100% PFE
Portfolio after 10yr
$35.7K
Annual income
$13,630.13/yr
Blended yield
38.16%
📊

Analyst Conviction Gap

Where Wall Street is split right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
AXON
Analyst Ratings
15
Buy
4
Hold
Consensus: Buy
Price Target
$750.00
+80.7% upside vs current
Range: $690.00 — $820.00
Altman Z
6.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
AXON buys
0
No recent congressional trades found for PFE or AXON in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFEAXON
Forward yield6.20%0.48%
Annual dividend / share$1.72$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%0%
Portfolio after 10y$51.1K$20.3K
Annual income after 10y$27,210.54$49.72
Total dividends collected$60.1K$490.00
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$27.50$750.00

Year-by-year: PFE vs AXON ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrAXON PortfolioAXON Income/yrGap
1$9,161$701.38$10,748$48.18$1.6KAXON
2$8,610$859.79$11,549$48.40$2.9KAXON
3$8,366$1,081.25$12,406$48.61$4.0KAXON
4$8,483$1,405.66$13,323$48.80$4.8KAXON
5$9,084$1,907.24$14,305$48.98$5.2KAXON
6$10,418$2,732.78$15,355$49.14$4.9KAXON
7$13,007$4,193.56$16,479$49.30$3.5KAXON
8← crossover$18,010$7,005.87$17,682$49.45+$328.00PFE
9$28,216$12,979.89$18,970$49.59+$9.2KPFE
10$51,081$27,210.54$20,347$49.72+$30.7KPFE

PFE vs AXON: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

AXONStock

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Full AXON Calculator →
📬

Get this PFE vs AXON comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.